Fresenius Medical Care AG & Co. KGaA: Release of a capital market information

Announcement pursuant to Article 5 (1) (b), (3) of Regulation (EU) No 596/2014 and Article 2 (3) of Delegated Regulation (EU) No 2016/1052

- Share buy-back - 2nd Interim Report and Final Report

In the period from 18 December 2017 until and including 21 December 2017, a total of 221,425 shares were repurchased within the framework of the share buy-back programme of Fresenius Medical Care AG & Co. KGaA ('Fresenius Medical Care'), which was announced on 8 December 2017 pursuant to Article 5 (1) (a) of Regulation (EU) No 596/2014 and Article 2 (1) of Delegated Regulation (EU) No 2016/1052.

The total volume of shares repurchased within the framework of this share buy-back in the period from 11 December until and including 21 December 2017 therefore amounts to 660,000 shares. The weighted average share price paid for these shares amounted to EUR 87.7788. This concludes the share buy-back programme.

The purchase of shares of Fresenius Medical Care within the framework of the share buy-back programme was carried out exclusively on the Frankfurt Stock Exchange via the XETRA trading platform by a credit institution commissioned by Fresenius Medical Care.

Detailed information on the transactions pursuant to Article 2 (3) of Delegated Regulation (EU) No 2016/1052 is available on Fresenius Medical Care's website at www.freseniusmedicalcare.com under section Investors.

Fresenius Medical Care AG & Co. KGaA

represented by Fresenius Medical Care Management AG

represented by its Management Board

Bad Homburg v.d.H., 27 December 2017